TTF-1, cytokeratin 7, 34βE12, and CD56/NCAM immunostaining in the subclassification of large cell carcinomas of the lung
TTF-1, cytokeratin 7, 34βE12, and CD56/NCAM immunostaining in the subclassification of large cell carcinomas of the lung
复制标题
DOI：
10.1309/9w8d3xcvlra3858a
复制
发表时间：
2004-12-01
影响因子：
3.5
通讯作者：
Cavazza, A
中科院分区：
文献类型：
--
作者：
Rossi, G;Marchioni, A;Cavazza, A
我们选择了甲状腺转录因子（TTF）-1、细胞角蛋白（CK）7、34 β E12和CD 56/神经细胞粘附分子（NCAM）4种染色的免疫板对45例支气管活检的肺大细胞癌（LCC）进行亚分类。所有病例均为大的肿瘤细胞增生，胞浆丰富，胞核呈泡状，核仁突出。免疫组化显示，27例肿瘤（60%）被细分为腺癌（TTF-1+/CK 7+，24例;仅CK 7+，3例），10例（22%）为鳞状细胞癌（仅34 β E12+），4例（9%）为LCC伴神经内分泌分化（CD 56+，TTF-1和CK 7染色，34 β E12-）。CK 7和34 β E12共表达（3例）或完全不表达（1例）。手术切除的肿瘤与23例中的21例相应的原始活检标本完全匹配;即使在活检中，一致的CD 56表达也是确认大细胞神经内分泌癌诊断的可靠标志物。我们的研究结果表明，建议的4染色的市售标记物可能有助于对LCC进行亚分类，即使是在小的活检材料中，验证针对肺癌分类的表达谱研究，并允许更一致的患者入组靶向治疗试验。
We selected a 4-stain immunopanel including thyroid transcription factor (TTF)-1, cytokeratin (CK) 7, 34betaE12, and CD56/neural cell adhesion molecule (NCAM) to subclassify a series of 45 pulmonary large cell carcinomas (LCCs) on bronchial biopsy. All cases consisted of a large tumor cell proliferation with abundant cytoplasm, vesicular nuclei, and prominent nucleoli. Immunohistochemically, 27 tumors (60%) were subclassified as adenocarcinoma (TTF-1+/CK7+, 24; CK7+ only, 3), 10 (22%) as squamous cell carcinoma (34betaE12+ only), and 4(9%) as LCC with neuroendocrine differentiation (CD56+, variably stained with TTF-1 and CK7, 34betaE12-). In 4 cases, the tumors coexpressed CK7 and 34betaE12 (3 cases) or were completely unstained (1 case). Surgically resected tumors matched exactly with the corresponding original biopsy specimens in 21 of 23 cases; consistent CD56 expression was a reliable marker in confirming a diagnosis of large cell neuroendocrine carcinoma even on biopsy. Our results suggest that the proposed 4-stain set of commercially available markers might help subclassify LCC even in small biopsy material, validating expression-profiling studies aimed at lung cancer classification and permitting more consistent patient enrollment for trials with targeted treatments.